How to prepare a Special Protocol Assessment request by study type

How do you prepare a Special Protocol Assessment request?

Establish that the protocol type and study status fit the SPA process, then submit one complete protocol with focused questions, supporting background, critical analysis details and relevant prior FDA discussions. Apply the study-type initiation boundaries and the explicit stability exception. Track FDA’s written agreement against the exact protocol version; SPA is not a guarantee of marketing approval.

Before you begin

FDA SPA process under the final April 2018 Revision 1 guidance. Protocol eligibility, prior interactions and study-start status must be established; agreement is not approval.

What you will prepare: One complete, type-specific protocol package with focused questions and a traceable agreement history.

Confirm an eligible protocol before requesting SPA

SPA seeks agreement on critical design and analysis elements of eligible studies intended to support a marketing application. The guidance covers animal carcinogenicity protocols, drug-substance/product stability protocols, Animal Rule efficacy protocols, trials intended to form the primary basis of an efficacy claim, and necessary clinical studies supporting biosimilarity/interchangeability. It is not a general certification service for every protocol.

Discuss the regulatory context in the appropriate prior FDA interaction. The guidance describes circumstances in which FDA may already know enough to accept a request without a separate prior meeting; do not assume that exception applies without evaluating the record. Apply the study-type initiation boundary in §VI.A footnote 21: clinical trials begin with participant screening or enrollment, Animal Rule efficacy studies with the first animal assigned to the protocol, and carcinogenicity studies with first dosing. An ongoing trial is not ordinarily appropriate for SPA. Stability studies have an explicit exception described below; do not apply a blanket pre-start exclusion to all four types.

Submit one complete protocol and answerable questions

The guidance recommends one protocol per request, submitted to the IND as a separate amendment with Form 1571 and a cover letter identifying the SPA request and protocol type. Use current electronic submission procedures rather than copying historical paper-copy instructions. Give the division advance awareness where appropriate and plan time to resolve important issues before study initiation.

Include the full protocol, planned analysis with critical statistical components, relevant background, prior FDA discussions and focused questions. Identify incomplete information explicitly with justification; an incomplete template is not a complete protocol. For each question state the proposed approach, rationale, evidence and consequence for the intended claim. Keep a version map so FDA’s response can be tied to the precise protocol reviewed.

1.8.1: connect a clinical protocol to its intended claim

For a clinical efficacy protocol, explain how the design addresses the elements of an adequate and well-controlled investigation: population, comparator, allocation/blinding, dose, endpoint, assessment schedule, sample size and planned analysis. Address multiplicity, missing data and important design assumptions at the level needed to assess the proposed claim. Identify relevant prior evidence and unresolved scientific issues instead of presenting a desired label as an agreed outcome.

For a necessary biosimilarity/interchangeability clinical study, state that regulatory objective and its evidence context rather than substituting a conventional new-drug efficacy claim. The final protocol and questions must fit the actual purpose. An SPA agreement does not establish concurrence with every minor protocol detail or guarantee filing or approval of the later application.

1.8.2: show why the carcinogenicity design is interpretable

Provide the complete carcinogenicity protocol and relevant background. Explain the species/model, dose-selection rationale, exposure support, duration, group design, endpoints, pathology approach and analysis plan. Connect the proposed study to the product’s development context and existing toxicology, including findings that complicate dose or model selection.

Create a short question-to-evidence table for the design choices requiring agreement. Do not invent a universal high dose, number of animals or model from the existence of this heading; those choices need the applicable product-specific scientific basis and current carcinogenicity guidance. If the dose-ranging evidence is unavailable, identify the gap before asking FDA to endorse the resulting dose selection.

1.8.3: explain why a stability protocol needs SPA

The guidance §V.B says standard stability protocols based on FDA/ICH principles generally do not need SPA. A request may be useful when the design differs significantly or raises questions not addressed by guidance. Establish advanced clinical development, completed product characterization and consistency of the intended manufacturing process, formulation and container closure with the product to be marketed.

For timing, §VI.A footnote 21 recommends submitting before initiation or the first measurement where possible, but expressly accepts stability-study SPA requests after initiation when ICH recommendations prove infeasible and FDA advice is needed. Describe the actual start and measurements already collected, the infeasible approach and why advice is now needed. This exception does not transfer to an already screening clinical trial.

Describe the nonstandard design, its scientific rationale, batches and product configurations, test strategy, proposed evaluation and how manufacturing steps could affect stability. Explain why the tests qualify the product for the proposed protocol. Do not describe agreement on a protocol as acceptance of a shelf life that the resulting data have not established.

1.8.4: anchor Animal Rule efficacy in an agreed model

Before the request, the guidance calls for FDA concurrence on the proposed animal model, including species, challenge agent and exposure conditions, and on the method for extrapolating animal data to a human dose/regimen. Preserve the actual interaction record establishing that foundation.

Include a detailed efficacy protocol, objectives, endpoints, analysis, evaluation criteria and data-quality plan. Supply a separate background document describing relevant data, assumptions and scientific/regulatory basis, plus a detailed translation plan for human dosing. If the model or extrapolation method remains unresolved, do not present the package as a final design awaiting a simple administrative signature.

Worked check: the study starts before agreement

Fictional exercise: an efficacy study has already begun when the team proposes its first SPA request. The pre-start eligibility boundary fails; renaming the protocol “final” does not fix it. Discuss the appropriate alternative interaction with FDA and describe the actual study status.

Change the scenario to a routine stability protocol that follows established guidance: reassess whether SPA is useful rather than making it an automatic filing. If that stability study has begun and the ICH approach proves infeasible, apply the express post-initiation exception and prepare the scientific justification instead of rejecting the request solely because work has started. Remove evidence of Animal Rule model concurrence: the preparation record must flag that missing prerequisite. After any agreement, preserve amendments and assess material changes through the guidance’s change/agreement process; an old agreement cannot be assumed to cover a redesigned study.

Make study status and protocol versions reviewable

Begin with an eligibility record before building the submission. A single “study not started” field is too ambiguous because the guidance uses different initiation events for different study types.

Screening exercise: the clinical team reports that nobody has received treatment, but participant screening began last week. Under §VI.A footnote 21's definition, the trial has begun for this purpose. Do not use first dosing as the clinical initiation test. Conversely, a nonstandard stability study that encounters an infeasible ICH approach requires assessment under the express exception rather than automatic rejection as already started.

Maintain a second record linking the submitted protocol version, question numbers, FDA response, agreed critical elements and subsequent amendments. Separate a request for agreement from documented concurrence. The evidence supporting a design also needs version control: changing an underlying assumption can affect the relevance of the earlier advice even if the protocol identifier remains the same.

Section VI.C distinguishes timely responses to readily correctable deficiencies from unsolicited protocol revisions, additional questions or complex new information during assessment. FDA ordinarily treats the latter circumstances as withdrawal of the original SPA submission and a new submission with a new response timeline. Coordinate changes rather than assuming every replacement file preserves the original review date. Section VI also describes consultation-related delays; the 45-day response framework is not automatic agreement if no letter arrives.

For changes after an agreement, assess the actual critical elements and use the guidance's written-agreement process where applicable. Do not silently treat a redesigned study as covered by an old letter. Use the meeting package guide to prepare a focused discussion of unresolved context, and the meeting correspondence guide to preserve the resulting advice.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides